Answers are grounded in this paper and cite their sources.
Single-center prospective study identifies N-NOSE and chemotactic behavior as predictors of recurrence in pancreatic cancer patients.
Abstract Background Pancreatic cancer (PC) remains one of the most lethal malignancies, with high recurrence rates even after curative-intent surgery. Current surveillance tools, including imaging and serum carbohydrate antigen 19 − 9, have limitations in specificity and sensitivity. N-NOSE is a urine-based assay using the chemotactic behavior of Caenorhabditis elegans to detect cancer-associated volatile organic compounds. This study prospectively evaluated the prognostic value of N-NOSE in patients undergoing curative surgery for resectable PC. Methods Twenty-four patients with resectable PC, all treated with preoperative gemcitabine plus S-1 chemotherapy followed by curative-intent pancreatectomy, were enrolled. The chemotaxis index was measured at three time points: before treatment, after preoperative chemotherapy, and postoperatively. Recurrence within two years was assessed. Univariate and multivariate logistic regression analyses were performed to identify predictors of recurrence, and recurrence-free survival was analyzed using Kaplan–Meier methods. Results During the two-year follow-up, 13 patients (54.2%) experienced recurrence. Univariate analysis identified pre-treatment platelet-to-lymphocyte ratio > 1.53 (p = 0.04), pathological lymph node metastasis (p = 0.04), and pre-treatment N-NOSE positivity (p = 0.007) as significant predictors. Multivariate analysis confirmed pre-treatment N-NOSE positivity as the only independent predictor (odds ratio: 3.10 × 10⁷; 95% CI: 11.38–; p = 0.03). In patients who recurred, the chemotaxis index increased significantly after surgery (p = 0.02), while remaining stable in non-recurrent cases. Conclusions Pre-treatment N-NOSE positivity and postoperative increases in chemotaxis index were associated with recurrence after curative-intent surgery for resectable PC. This non-invasive urine-based assay could provide valuable prognostic information to guide postoperative surveillance and individualized management.
No takes yet. Share an insight, caveat, or question.
Fukada et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: